Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 469

The DOI matches its Crossref record; 332 of the 332 references it cites were found in a registry or an index.

A Modern Approach to Dyslipidemia

Open access
Berberich, Amanda J, Hegele, Robert A·2022·Endocrine Reviews

Abstract

Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are commonly encountered in clinical practice and often have implications for cardiovascular risk and overall health. Recent advances in knowledge, recommendations, and treatment options have necessitated an updated approach to these disorders. Older classification schemes have outlived their usefulness, yielding to an approach based on the primary lipid disturbance identified on a routine lipid panel as a practical starting point. Although monogenic dyslipidemias exist and are important to identify, most individuals with lipid disorders have polygenic predisposition, often in the context of secondary factors such as obesity and type 2 diabetes. With regard to cardiovascular disease, elevated low-density lipoprotein cholesterol is essentially causal, and clinical practice guidelines worldwide have recommended treatment thresholds and targets for this variable. Furthermore, recent studies have established elevated triglycerides as a cardiovascular risk factor, whereas depressed high-density lipoprotein cholesterol now appears less contributory than was previously believed. An updated approach to diagnosis and risk assessment may include measurement of secondary lipid variables such as apolipoprotein B and lipoprotein(a), together with selective use of genetic testing to diagnose rare monogenic dyslipidemias such as familial hypercholesterolemia or familial chylomicronemia syndrome. The ongoing development of new agents—especially antisense RNA and monoclonal antibodies—targeting dyslipidemias will provide additional management options, which in turn motivates discussion on how best to incorporate them into current treatment algorithms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endrev/bnab037

Cites

332 of 332 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 332 references

Research works printed but not linked: 9

  1. Feingold, 2000, Introduction to lipids and lipoproteins
  2. Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet., 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
  3. Berg, 2002, U.S. Preventive Services Task Force: screening for lipid disorders in adults: recommendations and rationale, Am J Nurs., 102, 91
  4. Tsai, 2005, Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein, Clin Chim Acta., 358, 192, 10.1016/j.cccn.2005.02.008 · doi:10.1016/j.cccn.2005.02.008
  5. Koch, 2020, New Sampson low-density lipoprotein equation: better than Friedewald and Martin-Hopkins, Clin Chem., 66, 1120, 10.1093/clinchem/hvaa126 · doi:10.1093/clinchem/hvaa126
  6. Vinger, 1970, Ocular manifestations of hyperlipoproteinemia, Am J Ophthalmol., 70, 563, 10.1016/0002-9394(70)90890-1 · doi:10.1016/0002-9394(70)90890-1
  7. Hall, 2012, The best diagnosis is: eruptive xanthoma, Cutis., 90, 12
  8. US Food and Drug Administration., 2021, Statins: drug safety communication—FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy
  9. Kuehn, 2021, Evinacumab approval adds a new option for homozygous familial hypercholesterolemia with a hefty price tag, Circulation., 143, 2494, 10.1161/CIRCULATIONAHA.121.055463 · doi:10.1161/circulationaha.121.055463

Cited by

See all 469

Metadata

Authors
Berberich, A. J., & Hegele, R. A.
Venue
Endocrine Reviews
Published
2021-10-22
Volume
43
Issue
4
Pages
611-653
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W3205422331
Cited by
469
References
332
FWCI
53.38
Type
journal article
Language
en
Open access
hybrid
Funders
  • Canadian Institutes of Health Research
  • Heart and Stroke Foundation of Ontario (G-21-0031455)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Modern Approach to Dyslipidemia. https://app.cochat.ai/papers/10.1210/endrev/bnab037
The paper
Berberich, A. J., & Hegele, R. A. (2022). A Modern Approach to Dyslipidemia. Endocrine Reviews. https://doi.org/10.1210/endrev/bnab037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.